Constellation Pharmaceuticals Announces Appointment of Dr. Richard Levy to Board of Directors
06 Avril 2020 - 1:00PM
Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a
clinical-stage biopharmaceutical company using its expertise in
epigenetics to discover and develop novel therapeutics, today
announced that Richard Levy, M.D., has been appointed to its Board
of Directors.
Dr. Levy has nearly 30 years of experience in the pharmaceutical
and biotechnology sectors, where he held senior clinical
development positions at Incyte, Celgene, DuPont Pharmaceuticals,
and Sandoz / Novartis. He served as Executive Vice President and
Chief Drug Development and Medical Officer at Incyte, where from
2003 to 2016 he was responsible for the expansion of the clinical
development portfolio in oncology and inflammation. Dr. Levy
currently serves on the boards of Madrigal Pharmaceuticals, Kodiak
Sciences, Kiniksa Pharmaceuticals, and ArTara Therapeutics. From
2016 to 2019 he served as a senior advisor at Baker Brothers
Advisors, a health care investment company. Dr. Levy received his
M.D. from the University of Pennsylvania School of Medicine and
completed his training in Internal Medicine at the Hospital of the
University of Pennsylvania and a fellowship in Gastroenterology and
Hepatology at UCLA.
“I am excited to be joining the Constellation board,” said Dr.
Levy. “Constellation is developing a portfolio of promising
product candidates, including CPI-0610 in myelofibrosis and other
diseases. I look forward to working with my fellow board members
and with Constellation management to help make CPI-0610 part of the
new standard of care in myelofibrosis, as well as to advance the
company’s other programs.”
“We’re thrilled to have someone with Rich’s expertise on our
board,” said Jigar Raythatha, President and Chief Executive Officer
of Constellation Pharmaceuticals. “His medical and regulatory
experience will be invaluable as we work to advance CPI-0610.”
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage
biopharmaceutical company developing novel therapeutics that
selectively modulate gene expression to address serious unmet
medical needs in patients with cancer. The Company has a deep
understanding of how epigenetic and chromatin modifications in
cancer cells and in the tumor and immune microenvironment play a
fundamental role in driving disease progression and drug
resistance. Constellation is driving development of
the BET inhibitor CPI-0610 for the treatment of
myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI-0209
for the treatment of metastatic castration-resistant prostate
cancer and other cancers. The Company is also applying its broad
research and development capabilities to explore other novel
targets that directly and indirectly impact gene expression to fuel
a sustainable pipeline of innovative small-molecule product
candidates.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Such forward-looking statements include, but are not limited
to, the Company’s plans, strategies and prospects for its business
and statements regarding the development status of the Company’s
product candidates, the timing of availability of clinical trial
data and the Company’s ability to fund its operations until the
second half of 2022. All statements, other than statements of
historical facts, contained in this press release, including
statements regarding the implications of preliminary or interim
clinical data, the development status of the Company’s product
candidates, and the Company’s plans for future data presentations,
the Company’s strategy, future operations, future financial
position, prospects, plans and objectives of management, are
forward-looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in, or implied by, such forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks associated with the Company’s ability to: obtain and maintain
necessary approvals from the FDA and other regulatory authorities;
continue to advance its product candidates in clinical trials;
whether preliminary or interim data from a clinical trial will be
predictive of the final results of the trial; replicate in later
clinical trials positive results found in preclinical studies and
early-stage clinical trials of CPI-0610, CPI-1205 and CPI-0209;
advance the development of its product candidates under the
timelines it anticipates, or at all, in current and future clinical
trials; obtain, maintain, or protect intellectual property rights
related to its product candidates; manage expenses; and raise the
substantial additional capital needed to achieve its business
objectives. CPI-0610, CPI-1205 and CPI-0209 are investigational
therapies and have not been approved by the FDA (or any other
regulatory authority). For a discussion of other risks and
uncertainties, any of which could cause the Company’s actual
results to differ from those contained in the forward-looking
statements, see the “Risk Factors” section, as well as discussions
of potential risks, uncertainties and other important factors, in
the Company’s most recent filings with the Securities and
Exchange Commission, including the Company’s Annual Report on Form
10-K for the full year ended December 31, 2019. In addition,
the forward-looking statements included in this press release
represent the Company’s views as of the date hereof and should not
be relied upon as representing the Company’s views as of any date
subsequent to the date hereof. The Company anticipates that
subsequent events and developments will cause the Company’s views
to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so.
Contact Ronald Aldridge Investor
RelationsConstellation Pharmaceuticals+1
617-714-0539ron.aldridge@constellationpharma.com
Lauren ArnoldMedia RelationsMacDougall Biomedical
Communications+1 781-235-3060larnold@macbiocom.com
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Constellation Pharmaceut... (NASDAQ:CNST)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024